TransMedics Group (NASDAQ:TMDX) Stock Breaks Above Fifty Day Moving Average – Here’s What Happened

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $79.61 and traded as high as $88.44. TransMedics Group shares last traded at $88.24, with a volume of 3,950,703 shares traded.

TransMedics Group News Roundup

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wall Street Zen raised TransMedics Group from a “sell” rating to a “hold” rating in a research report on Saturday. Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a report on Friday. Barclays initiated coverage on TransMedics Group in a report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Finally, UBS Group cut their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $118.60.

TransMedics Group Price Performance

The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The company has a 50-day moving average of $79.61 and a 200 day moving average of $93.17. The stock has a market capitalization of $3.05 billion, a PE ratio of 23.91, a PEG ratio of 0.92 and a beta of 2.14.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.21. The firm had revenue of $203.01 million during the quarter, compared to analyst estimates of $178.06 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The business’s quarterly revenue was up 41.1% compared to the same quarter last year. During the same period last year, the company posted $0.66 EPS. Sell-side analysts predict that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Insider Activity

In related news, Director David Weill acquired 1,336 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was bought at an average cost of $81.63 per share, with a total value of $109,057.68. Following the transaction, the director owned 16,392 shares of the company’s stock, valued at $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently bought and sold shares of the business. Ascentis Independent Advisors bought a new position in TransMedics Group during the 1st quarter valued at approximately $30,000. Silvant Capital Management LLC bought a new position in TransMedics Group during the second quarter valued at about $26,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of TransMedics Group by 95.0% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company’s stock valued at $45,000 after purchasing an additional 207 shares in the last quarter. State of Wyoming bought a new position in TransMedics Group during the 2nd quarter worth approximately $31,000. Finally, Ancora Advisors LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth $33,000. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.